About Probable tRNA methyltransferase 9B
Probable tRNA methyltransferase 9B (TRMT9B) is a protein
from Homo sapiens identified by UniProt accession
Q9P272, 454 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | Probable tRNA methyltransferase 9B |
| UniProt accession | Q9P272 |
| Gene | TRMT9B |
| Organism | Homo sapiens |
| Length | 454 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (109)
Diseases linked to this target (Open Targets).
- cortical thickness · score 0.35
- hemoglobin measurement · score 0.31
- protein measurement · score 0.27
- metabolite measurement · score 0.16
- self reported educational attainment · score 0.13
- apolipoprotein A 1 measurement · score 0.11
- balding measurement · score 0.10
- early-onset non-syndromic cataract · score 0.10
- neoplasm · score 0.10
- emphysema imaging measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P272-F1 | alphafold | PREDICTED | 61.77 | — |
Amino-acid sequence (454 residues)
MDHEAAQLEK QHVHNVYEST APYFSDLQSK AWPRVRQFLQ EQKPGSLIAD IGCGTGKYLK VNSQVHTVGC DYCGPLVEIA RNRGCEAMVC DNLNLPFRDE GFDAIISIGV IHHFSTKQRR IRAIKEMARV LVPGGQLMIY VWAMEQKNRH FEKQDVLVPW NRALCSQLFS ESSQSGRKRQ CGYPERGHPY HPPCSECSCS VCFKEQCGSK RSHSVGYEPA MARTCFANIS KEGEEEYGFY STLGKSFRSW FFSRSLDEST LRKQIERVRP LKNTEVWASS TVTVQPSRHS SLDFDHQEPF STKGQSLDEE VFVESSSGKH LEWLRAPGTL KHLNGDHQGE MRRNGGGNFL DSTNTGVNCV DAGNIEDDNP SASKILRRIS AVDSTDFNPD DTMSVEDPQT DVLDSTAFMR YYHVFREGEL CSLLKENVSE LRILSSGNDH GNWCIIAEKK RGCD
Explore Probable tRNA methyltransferase 9B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets